BeEAM (bendamustine, etoposide, cytarabine, melphalan) prior to autologous stem cell transplant for chemosensitive relapses in patients with follicular lymphoma: a prospective multicentre phase II study in Lymphoma Study Association centres † | Zendy

Ghesquières Hervé | Zendy; Dalban Cécile | Zendy; NicolasVirelizier Emmanuelle | Zendy; Jardin Fabrice | Zendy; Le Bras Fabien | Zendy; Le Gouill Steven | Zendy; Casasnovas Olivier | Zendy; Vizoso Séraphine | Zendy; Hernandez Caroline | Zendy; Metzger Séverine | Zendy; Pérol David | Zendy; Cartron Guillaume | Zendy

Premium

BeEAM (bendamustine, etoposide, cytarabine, melphalan) prior to autologous stem cell transplant for chemosensitive relapses in patients with follicular lymphoma: a prospective multicentre phase II study in Lymphoma Study Association centres †

Author(s) -

Ghesquières Hervé,

Dalban Cécile,

NicolasVirelizier Emmanuelle,

Jardin Fabrice,

Le Bras Fabien,

Le Gouill Steven,

Casasnovas Olivier,

Vizoso Séraphine,

Hernandez Caroline,

Metzger Séverine,

Pérol David,

Cartron Guillaume

Publication year - 2021

Publication title -

british journal of haematology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.907

H-Index - 186

eISSN - 1365-2141

pISSN - 0007-1048

DOI - 10.1111/bjh.17279

Subject(s) - bendamustine , medicine , melphalan , etoposide , follicular lymphoma , transplantation , salvage therapy , autologous stem cell transplantation , cytarabine , oncology , gastroenterology , surgery , regimen , chemotherapy , lymphoma , rituximab

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research